{
    "root": "302b5697-b550-7973-e063-6294a90a78c6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ciprofloxacin",
    "value": "20250312",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE)",
            "code": "461P5CJN6T"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "CIPROFLOXACIN HYDROCHLORIDE",
            "code": "4BA73M5E37"
        }
    ],
    "indications": "ciprofloxacin tablets 250 mg , 500 mg , 750 mg fluoroquinolone antibacterial indicated adults ( ≥18 years age ) following infections caused designated , susceptible bacteria pediatric patients indicated : skin skin structure infections ( 1.1 ) bone joint infections ( 1.2 ) complicated intra-abdominal infections ( 1.3 ) infectious diarrhea ( 1.4 ) typhoid fever ( enteric fever ) ( 1.5 ) uncomplicated cervical urethral gonorrhea ( 1.6 ) inhalational anthrax post-exposure adult pediatric patients ( 1.7 ) plague adult pediatric patients ( 1.8 ) chronic bacterial prostatitis ( 1.9 ) lower respiratory tract infections ( 1.10 ) acute exacerbation chronic bronchitis urinary tract infections ( 1.11 ) urinary tract infections ( uti ) acute uncomplicated cystitis complicated uti pyelonephritis pediatric patients acute sinusitis ( 1.12 ) usage reduce development drug-resistant bacteria maintain effectiveness ciprofloxacin antibacterial drugs , ciprofloxacin used treat prevent infections proven strongly suspected caused bacteria . ( 1.13 )",
    "contraindications": "ciprofloxacin tablets administered orally described appropriate guidelines tables .",
    "warningsAndPrecautions": "ciprofloxacin tablets usp ( white off-white capsule-shaped tablets ) containing 500 mg ciprofloxacin engraved “ cti 223 ” bottle 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( ndc 43063-923-02 ) bottle 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( ndc 43063-923-04 ) bottle 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( ndc 43063-923-06 ) bottle 10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( ndc 43063-923-10 ) bottle 14. . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( ndc 43063-923-14 ) bottle 20. . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( ndc 43063-923-20 ) bottle 28. . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( ndc 43063-923-28 ) bottle 30. . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( ndc 43063-923-30 ) store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "known hypersensitivity ciprofloxacin quinolones ( 4.1 , 5.6 , 5.7 ) concomitant tizanidine ( 4.2 )",
    "indications_original": "Ciprofloxacin Tablets 250 mg, 500 mg, and 750 mg are a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: Skin and Skin Structure Infections ( 1.1 ) Bone and Joint Infections ( 1.2 ) Complicated Intra-Abdominal Infections ( 1.3 ) Infectious Diarrhea ( 1.4 ) Typhoid Fever (Enteric Fever) ( 1.5 ) Uncomplicated Cervical and Urethral Gonorrhea ( 1.6 ) Inhalational Anthrax post-exposure in adult and pediatric patients ( 1.7 ) Plague in adult and pediatric patients ( 1.8 ) Chronic Bacterial Prostatitis ( 1.9 ) Lower Respiratory Tract Infections ( 1.10 ) Acute Exacerbation of Chronic Bronchitis Urinary Tract Infections ( 1.11 ) Urinary Tract Infections (UTI) Acute Uncomplicated Cystitis Complicated UTI and Pyelonephritis in Pediatric Patients Acute Sinusitis ( 1.12 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin and other antibacterial drugs, Ciprofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.13 )",
    "contraindications_original": "Ciprofloxacin Tablets should be administered orally as described in the appropriate Dosage Guidelines tables.",
    "warningsAndPrecautions_original": "Ciprofloxacin Tablets USP (white to off-white capsule-shaped tablets) containing\n                  500 mg of ciprofloxacin and engraved with “CTI 223”\n                  Bottle of 2...............................(NDC 43063-923-02)\n                  Bottle of 4...............................(NDC 43063-923-04)\n                  Bottle of 6...............................(NDC 43063-923-06)\n                  Bottle of 10.............................(NDC 43063-923-10)\n                  Bottle of 14.............................(NDC 43063-923-14)\n                  Bottle of 20.............................(NDC 43063-923-20)\n                  Bottle of 28.............................(NDC 43063-923-28)\n                  Bottle of 30.............................(NDC 43063-923-30)\n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Known hypersensitivity to Ciprofloxacin or other quinolones ( 4.1 , 5.6 , 5.7 ) Concomitant administration with tizanidine ( 4.2 )"
}